The Cross-Border Biotech Blog

Biotechnology, Health and Business in Canada, the United States and Worldwide

Tag Archives: DxS

Trends Update — Personalized Medicine: DxS’ Latest Companion Diagnostics Deal

As personalized medicine inches toward becoming the standard of care for cancer, the question of who pays for the genotyping becomes more important.  A deal announced Friday between DxS, a molecular diagnostics company, and Boehringer Ingelheim suggests that pharma companies will end up footing at least part of the bill by paying for the development (and marketing?) [...]

Follow

Get every new post delivered to your Inbox.

Join 84 other followers